MedPath

Ramelteon(melatonin receptor agonist)for neuromuscular degenerative disease and neuroimmunological disease;examination for safety

Not Applicable
Conditions
neuromuscular degenerative disease and neuroimmunological disease
Registration Number
JPRN-UMIN000006298
Lead Sponsor
Yokohama city University Graduate School of Medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

As a rule ,these patients are excluded; patients whose %VC are 50% or less,patients who has respiratory disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
o significant difference on ODI3 before and after Ramelteon administration.
Secondary Outcome Measures
NameTimeMethod
Ramelteon utility should be proven by sleep score.
© Copyright 2025. All Rights Reserved by MedPath